On Thursday, Shares of Revance Therapeutics Inc (NASDAQ:RVNC), gained 40.63% to $37.59.
Revance Therapeutics, declared positive 24-week results recently from its multi-center BELMONT Phase 2 active comparator study of injectable RT002. The ongoing study for the treatment of glabellar lines in 268 subjects contrast the safety, efficacy and duration of effect of three doses of RT002 against placebo, and current market leader, BOTOX Cosmetic/ VISTABEL(R). The topline interim data showed that RT002- a botulinum toxin type A investigational drug product candidate for injection- achieved its primary efficacy measurement for all three doses at 4 weeks. The study demonstrated 6-month RT002 median duration of effect based upon at least 1-point improvement in glabellar lines at maximum frown on the Investigator Global Assessment-Facial Wrinkle Severity (IGA-FWS) scale.
Key interim results of the BELMONT trial
- The 4 week primary efficacy measurement of at least 1-point improvement in frown lines based on the IGA-FWS scale for all three doses (20 Units, 40 Units and 60 Units) of RT002 was highly statistically noteworthy(p < 0.001) as contrast to placebo for all three doses.
- All doses of RT002 achieved a 100 percent response rate of at least 1-point improvement in frown lines, based on the IGA-FWS scale at 4 weeks as contrast to a 95 percent response rate for BOTOX Cosmetic.
- RT002 efficacy showed a dose response. RT002 40U was statistically noteworthy to BOTOX Cosmetic on all three responder definitions for the IGA-FWS median duration of effect. On the IGA-FWS duration of response.RT002 demonstrated a 23.6 week median duration as contrast to BOTOX Cosmetic with an 18.8 week median duration (p=0.020).
- More than twice as many RT002 40U and 60U subjects in the study maintained none or mild wrinkles on the IGA-FWS scale as contrast to BOTOX Cosmetic at Week 16 (p<=0.002).
- Subject-stated outcomes were consistent with investigator findings of duration and efficacy of RT002.
Revance Therapeutics, Inc., a clinical-stage specialty biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications.
Shares of QUALCOMM, Inc. (NASDAQ:QCOM), declined -0.44% to $60.00, during its last trading session.
Qualcomm Incorporated, declared that Brian Modoff has joined the Company as executive vice president of strategy, M&A and ventures, reporting directly to Steve Mollenkopf, CEO of Qualcomm. Brian will have companywide oversight for strategy, M&A and the venture investment portfolio.
In his newly created role, Modoff will partner closely with the Executive Committee to assist define Qualcomm’s planned direction and long-term vision and to ensure strong cohesion and alignment with all planned planning efforts throughout the organization. Modoff is a seasoned industry strategist who most recently served as a Managing Director in Equity Research at Deutsche Bank Securities. With more than 20 years of experience in the communications sector, he has offered guidance and advice to many companies for IPOs, mergers and acquisitions and venture capital funding. Preceding to working on Wall Street, he held various leadership positions at Rockwell and served in the US Navy. Modoff has a Master of International Administration from the American Graduate School of International Administration (Thunderbird) in Glendale, Arizona and received his B.A. in Economics from California State University, Fullerton.
QUALCOMM Incorporated designs, develops, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, and the United States. The company operates through three segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Planned Initiatives (QSI).
Finally, Shares of CMS Energy Corporation (NYSE:CMS), ended its last trade with -1.38% loss, and closed at $35.75.
CMS Energy declared, stated net income of $148 million, or $0.53 per share, for the third quarter of 2015 and $417 million, or $1.51 per share, for the first nine months of the year. Adjusted earnings per share for the third quarter and first nine months were the same as stated amounts.
CMS Energy raised the low end of its 2015 adjusted earnings per share guidance by a penny from $1.86-$1.89 to $1.87-$1.89, consistent with performance at the high end of its long-term plan to grow earnings per share at 5% to 7%.
For the first nine months of 2015, CMS Energy achieved high marks for customer satisfaction as it focused on reinvestments in its electric and natural gas operations, affordability and transitioning to cleaner energy sources.
“We are transitioning to a cleaner energy portfolio, which benefits our customers and Michigan as it develops a compliance strategy for the federal Clean Power Plan,” said John Russell, president and chief executive officer for CMS Energy and its principal partner, Consumers Energy.
CMS Energy Corporation operates as an energy company primarily in Michigan, the United States. The company’s Electric Utility segment engages in the generation, purchase, distribution, and sale of electricity to residential, commercial, and various industrial customers in Michigan’s Lower Peninsula.